Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema.

Trial Profile

Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DERMATUX
  • Most Recent Events

    • 07 Jun 2016 Results assessing efficacy presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 17 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 25 Apr 2012 Planned end date changed from 1 Apr 2016 to 1 Mar 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top